**Question:** Which of the following is NOT used in treatment of hairy cell leukemia -

A. Rituximab
B. Chemotherapy
C. Interferon-alpha
D. Photopheresis

**Correct Answer: D. Photopheresis.**

**Core Concept:**
Hairy cell leukemia (HCL) is a rare form of leukemia characterized by the accumulation of hairy cells in the bone marrow, peripheral blood, and spleen. Treatment for HCL involves a combination of approaches to target the abnormal cells and alleviate symptoms. The correct answer, **Photopheresis**, is an extracorporeal photopheresis (ECP) therapy that involves removing blood, exposing it to ultraviolet light (photopheresis), reinfusing it back into the patient (apheresis). While ECP has shown some efficacy in treating HCL, it is not commonly used as a first-line treatment option due to its limitations and potential side effects.

**Why the Correct Answer is Right:**
Rituximab (A) is a monoclonal antibody targeting CD20, a cell surface antigen expressed on hairy cells, making it a crucial component in the treatment of HCL. Chemotherapy (B) is used to target and kill rapidly dividing cells, including hairy cells. Interferon-alpha (C) is a cytokine that modulates the immune system and has shown efficacy in treating HCL by inducing hairy cell apoptosis and reducing splenomegaly. However, photopheresis (D) is not a standard treatment for HCL, making it the incorrect option in comparison to the other treatment modalities.

**Why Each Wrong Option is Incorrect:**
Photopheresis is an extracorporeal immunomodulatory therapy that aims to induce apoptosis (cell death) of lymphocytes and monocytes. While it has shown some success in treating HCL, its limited efficacy, high cost, and potential side effects (autoimmune reactions, infections) make it an inferior choice compared to other treatments. Chemotherapy (B) and interferon (C) are more commonly used and effective treatments for HCL with fewer side effects. Rituximab (A) is a monoclonal antibody targeting CD20, a cell surface antigen expressed on hairy cells, making it a crucial component in the treatment of HCL.

**Clinical Pearls:**
1. Extracorporeal photopheresis is a valuable option for HCL treatment, but its limitations and side effects make other treatments more suitable in most cases.
2. Monoclonal antibodies, such as rituximab (A), have emerged as a crucial component in the treatment of HCL due to their ability to target CD20 antigen on hairy cells.
3. Chemotherapy (B) and interferon (C) are more commonly used and effective treatments for HCL, as they address the underlying pathology of hairy cell proliferation and have fewer side effects than photopheresis.